ARTICLE | Product Development
Could an approval of Biogen’s Alzheimer’s therapy still be an option?
Aducanumab’s chances of approval are slim, but they’re not zero. KOLs weigh in on what a path to approval could look like.
November 21, 2020 4:50 AM UTC
For almost any other compound, the nearly unanimous advisory committee vote that Biogen’s Alzheimer’s therapy aducanumab suffered would make its chances of approval vanishingly small. But this mAb has defied gravity before.
FDA’s clear desire to authorize the anti-amyloid agent begs the question of whether a path to market may still exist – and what it would look like...